Are we ready to treat high-risk patients with DLBCL differently? Relapsed/refractory disease – a continued area of unmet me

EHA Library, H Tilly, 312355

Follicular lymphoma from genetics to the clinic

EHA Library, Gilles Salles, 313417

Questions and Discussion

EHA Library, Nicola GÖKBUGET, 312326

Asparaginase pharmacokinetics and pharmacodynamics

EHA Library, M Relling, 312328

Effective management of VOCs: Overcoming barriers and finding solutions

EHA Library, Ifeyinwa Osunkwo, 312333

Living with SCD: Understanding the consequences

EHA Library, R Colombatti, 312334

Summary and close

EHA Library, Ifeyinwa Osunkwo, 312336

Recommendations and consensus for the use of IgG therapy in patients with hematological malignancies and secondary immune d

EHA Library, M Albert, 312340

Panel Discussion & Closing

EHA Library, Faculty / Presenters, 312341

Focus on bispecific antibody safety: are there any new signals?

EHA Library, Martin Hutchings, 312342

Session Opening & Zooming in on T-cell engaging therapies in NHL

EHA Library, S Dietrich, 312345

Understanding the latest clinical data for bispecific antibodies and other T-cell engaging therapies in NHL

EHA Library, Sarit Assouline, 312343

What impact will CD20/CD3 bispecific antibodies have on the evolving NHL treatment landscape?

EHA Library, Franck Morschhauser, 312344

Future perspectives and closing remarks

EHA Library, Tadeusz Robak, 312339

Session Opening & The burden of infection in Chronic Lymphocytic Leukemia and Multiple Myeloma/COVID-19 in patients with ch

EHA Library, Tadeusz Robak, 312338

Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy

EHA Library, Marion Subklewe, 312337

Impact and treatment of SCD: Hearing the patient viewpoint

EHA Library, John James, 312335

Welcome and Introduction

EHA Library, Ifeyinwa Osunkwo, 312332

COVID-19 and SCD: The experts in conversation

EHA Library, Ifeyinwa Osunkwo, 312331

Toxicities in adult versus pediatric ALL patients and consequences for management

EHA Library, K Schmiegelow, 312330

Q&A

EHA Library, Faculty / Presenters, 312325

Q&A

EHA Library, Faculty / Presenters, 312327

Efficacy, tolerability and management strategies in the GMALL trials

EHA Library, Nicola GÖKBUGET, 312329

Iron overload, monitoring and management

EHA Library, Ali Taher, 313425

Real life CAR T treatment

EHA Library, Catherine Thieblemont, 313427

Red cell transfusions: Current best practice and how to further optimize?

EHA Library, Marlijn Hoeks, 313430

ALL subtypes

EHA Library, Ilaria Iacobucci, 313431

Advances in risk stratification in pediatric acute lymphoblastic leukemia

EHA Library, Anthony Moorman, 313432

Novel agents for phase 3 trials

EHA Library, Michel Zwaan, 313433

New insights in the pathogenesis of autoimmune hemolytic diseases

EHA Library, Wilma Barcellini, 313434

Potentially druggable targets in transformed disease

EHA Library, Davide Rossi, 313478

Drug induced immune hemolytic disease: Diagnostic challenges

EHA Library, Quentin A Hill, 313435

Niche contributions to bone marrow failure and clonal evolution in MDS

EHA Library, Marc Raaijmakers, 313482

Management of post allogeneic HCT auto/alloimmune cytopenia

EHA Library, Andreas Holbro, 313436

Novel treatment options

EHA Library, Subarna Chakravorty, 313426

Epidemiology of Hbpathies in Europe

EHA Library, Fred Piel, 313429

Vulnerabilities of indolent lymphomas: The tumor and the microenvironment

EHA Library, Leticia Quintanilla de Fend, 313437

Building blocks to optimize CLL treatment

EHA Library, Thorsten Zenz, 313440

Genetic heterogeneity of congenital neutropenias

EHA Library, Karl Welte, 313444

New drugs and BMT: How to choose

EHA Library, Maria Domenica Cappellini, 313450

Primary mediastinal lymphoma

EHA Library, Maurizio Martelli, 313452

Immunotherapy and other novel immunological therapies

EHA Library, Daniel Olive, 313458

Natural Killer Cell-Mediated Immunosurveillance of leukemia

EHA Library, Yenan Bryceson, 313459

Basis of iron regulation for erythropoiesis

EHA Library, Laura Silvestri, 313461

Classification and clinical approach to atypical microcytic anemias

EHA Library, Patricia Aguilar Martinez, 313462

Treatment of the older patient with AML

EHA Library, Courtney DiNardo, 313469

Update on oral contraception and VTE

EHA Library, Marc Blondon, 313480

The molecular basis of p53 mutations in MDS

EHA Library, Benjamin Ebert, 313483

CAR T cells

EHA Library, Paula Rodríguez-Otero, 313424

T-cell engaging antibodies for hematological diseases from approved therapies to new indications

EHA Library, Hermann Einsele, 313423

Improving efficacy and persistence of CAR-T cell

EHA Library, Christian Chabannon, 313422

Hydroxyurea: Fertility a still open question in adulthood

EHA Library, David Rees, 313421

Testicular lymphoma

EHA Library, Annalisa Chiappella, 313453

Management of MM patients with high-risk disease

EHA Library, Jesús San Miguel, 313457

Eosinophilia

EHA Library, Andreas Reiter, 313466

Inherited platelet disorders and mutations in hematopoietic transcription factors

EHA Library, A. Koneti Rao, 313473

Immune thrombocytopenia (ITP): New insights on pathophysiology

EHA Library, John Semple, 313474

TTP vs HUS - Novel insights

EHA Library, Marie Scully, 313475

Biological basis of transformation

EHA Library, Ulf Klein, 313476

Current treatment options for transformed disease

EHA Library, Silvia Montoto, 313477

Sickle cell disease as a chronic problem

EHA Library, Marianne de Montalambert, 313485

REAL-LIFE TREATMENT OUTCOME OF FIRST-LINE REGIMEN FOR NON-TRANSPLANT ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Yasutaka Kakinoki, 293515

LIMITED EFFICACY OF DARATUMUMAB IN MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE

EHA Library, Tomas Jelinek, 293520

A SYSTEMATIC LITERATURE REVIEW TO ASSESS EFFICACY OF TREATMENTS IN TRIPLE-CLASS EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS

EHA Library, Faith Davies, 293523

FRONTLINE (FL) TREATMENT PATTERNS AND USE OF MAINTENANCE THERAPY (MT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS NOT RECEIVING FL STEM CELL TRANSPLANT (NSCT)

EHA Library, Dasha Cherepanov, 293524

THE PERCENTAGE OF ABNORMAL PLASMA CELL AMONG TOTAL BM PLASMA CELLS PREDICTED THE DISEASE PROGRESSION AFTER MRD REAPPEARANCE IN PATIENTS WITH TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Jingli Gu, 293525

IXAZOMIB REAL-LIFE-SETTING USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: REMIX, A PROSPECTIVE, NON-INTERVENTIONAL STUDY

EHA Library, Lauriane Filliatre-Clément, 293526

POMALIDOMIDE-BASED TREATMENT IN RELAPSED REFRACTORY MULTIPLE MYELOMA: ANALYSIS BY FIRST-LINE MELPHALAN THERAPY IN A EUROPEAN POST-AUTHORIZATION SAFETY STUDY

EHA Library, Niels Abildgaard, 293513

ASSESSMENT OF DISEASE BURDEN IN TERMS OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MULTIPLE MYELOMA NOT ELIGIBLE FOR ASCT IN SPAIN: UPDATE OF THE QOLMMBUS STUDY

EHA Library, Javier De La Rubia, 293511

ORTHOTOPIC HEART TRANSPLANT FACILITATED AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR LIGHT-CHAIN AMYLOIDOSIS: LONG-TERM OUTCOMES

EHA Library, Rammurti Kamble, 293510

THROMBOTIC MICROANGIOPATHY IN MYELOMA PATIENTS TREATED WITH FRONTLINE CARFILZOMIB ON THE PHASE 2 CARDAMON TRIAL

EHA Library, Marquita Camilleri, 293509

ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS WITH 1Q21 GAIN: INSIGHTS FROM PHASE 1 AND PHASE 3 STUDIES

EHA Library, PAUL RICHARDSON, 293508

DREAMM-2: ASSESSING EFFICACY VIA INDIRECT COMPARISON OF SINGLE-AGENT BELANTAMAB MAFODOTIN VERSUS SELINEXOR PLUS DEXAMETHASONE COMBINATION IN ANTI-CD38 EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Rakesh Popat, 293507

POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: OPTIMISMM SUBANALYSIS

EHA Library, Fredrik Schjesvold, 293506

RESPONSE TO CARFILZOMIB REGIMENS AMONG PATIENTS WITH EARLY OR LATE RELAPSE FOLLOWING PRIOR MULTIPLE MYELOMA THERAPY: A SUBGROUP ANALYSIS FROM A PROSPECTIVE OBSERVATIONAL STUDY ACROSS EUROPE AND ISRAEL

EHA Library, Evangelos Terpos, 293501

TREATMENT PATTERNS OF LENALIDOMIDE DELIVERY AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS IN REAL-WORLD SETTINGS: A MULTI-CENTER RETROSPECTIVE STUDY

EHA Library, Wolfgang Willenbacher, 293499

EFFICACY AND TOXICITY OF AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION IN ELDERLY MYELOMA PATIENTS

EHA Library, Sejla Hujic, 293498

QUALITY OF LIFE IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH THE BCMA-TARGETED CAR T CELL THERAPY IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121): RESULTS FROM THE KARMMA TRIAL

EHA Library, Julia Braverman, 293491

LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE (RD) AS FIRST LINE TREATMENT OF NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE TO STEM CELL TRANSPLANTATION: REAL LIFE ITALIAN EXPERIENCE

EHA Library, ALESSANDRA POMPA, 293495

REAL-WORLD OUTCOMES OF BELANTAMAB MAFODITIN TREATMENT FOR PATIENTS WITH RELAPSED/REFRACTORY MYELOMA VIA GSK EXPANDED ACCESS PROGRAM.

EHA Library, Tamir Shragai, 293493

PROFILE CHARACTERISTICS OF LONG-TERM SURVIVORS IN MULTIPLE MYELOMA

EHA Library, Florence Sabirou, 293530

EVOLVING OUTCOMES IN MM REAL-WORLD PRACTICE: 20-YEARS SINGLE CENTER EXPERIENCE

EHA Library, Claudia Bellofiore, 293529

CORTICOSTERIOD TAPERING IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA RECEIVING SUBCUTANEOUS DARATUMUMAB (DARA SC): PART 3 OF THE OPEN-LABEL, MULTICENTER, PHASE 1B PAVO STUDY

EHA Library, Hareth Nahi, 293528

DREAMM-2: SINGLE-AGENT BELANTAMAB MAFODOTIN (GSK2857916) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) AND HIGH-RISK (HR) CYTOGENETICS

EHA Library, Suzanne Trudel, 293527

PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH TRIPLE CLASS REFRACTORY MULTIPLE MYELOMA

EHA Library, Maneesha Mehra, 293522

DREAMM-6: SAFETY AND TOLERABILITY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH BORTEZOMIB/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Rakesh Popat, 293521

HORIZON (OP-106): AN EXPLORATORY ANALYSIS OF TIME TO NEXT TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED MELFLUFEN PLUS DEXAMETHASONE

EHA Library, María-Victoria Mateos, 293519

HEALTH-RELATED QUALITY OF LIFE IN HEAVILY PRE-TREATED AND RENALLY IMPAIRED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE: ICARIA-MM STUDY

EHA Library, Meletios Dimopoulos, 293518

REAL-LIFE BORTEZOMIB MAINTENANCE PROVIDES SIMILAR OUTCOMES TO THOSE REPORTED WITH ALTERNATIVE MAINTENANCE STRATEGIES: A MULTISITE RETROSPECTIVE STUDY.

EHA Library, Efrat Luttwak, 293517

IMMUNOPARESIS AT DIAGNOSIS IS AN ADVERSE PROGNOSTIC FACTOR FOR PROGRESSION FREE-SURVIVAL AND OVERALL SURVIVAL IN MULTIPLE MYELOMA

EHA Library, Teresa Ribeiro, 293516

A NATIONWIDE, POPULATION-BASED REGISTER OF SYSTEMIC AL AMYLOIDOSIS PATIENTS IN THE NETHERLANDS; PRELIMINARY RESULTS OF 205 PATIENTS DIAGNOSED IN 2017 AND 2018

EHA Library, Mirian Brink, 293514

AMINO ACID-BASED FLUCICLOVINE PET/CT DETECTION OF MULTIPLE MYELOMA

EHA Library, Jakob Nordberg Nørgaard, 293512

REAL WORLD EXPERIENCE OF SALVAGE 2ND AUTOGRAFT FOR RELAPSED MYELOMA: TIME TO PROGRESSION AFTER 1ST AUTOGRAFT AND CONSOLIDATION/MAINTENANCE IMPROVE PROGRESSION FREE SURVIVAL

EHA Library, Huw Richards, 293505

THE PROGNOSTIC IMPACT OF 1Q21 GAIN IN NEWLY DIAGNOSED MULTIPLE MYELOMA. A MULTICENTER STUDY.

EHA Library, Rafael Rios-Tamayo, 293503

PROGNOSTIC IMPACT OF CYTOGENETIC EVOLUTION AND ACQUISITION OF DEL(17P) IN MULTIPLE MYELOMA

EHA Library, Aleksander Salomon-Perzyński, 293502

ISATUXIMAB SHORT-DURATION FIXED-VOLUME INFUSION COMBINATION THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: FINAL RESULTS OF A PHASE 1B FEASIBILITY/SAFETY STUDY

EHA Library, Saad Z. Usmani, 293500

DREAMM-2: SINGLE-AGENT BELANTAMAB MAFODOTIN (GSK2857916) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) AND RENAL IMPAIRMENT

EHA Library, Hans Lee, 293497

DIFFUSION WEIGHTED WHOLE BODY MRI FOR EVALUATION OF RESPONSE AFTER ASCT IN MULTIPLE MYELOMA

EHA Library, Gregorio Barilà, 293494

BENEFICIAL EFFECT ON OVERALL SURVIVAL OF EARLY SALVAGE TREATMENT WITH SECOND-GENERATION NOVEL AGENTS AT BIOCHEMICAL RELAPSE: A REAL-WORLD SINGLE CENTER EXPERIENCE

EHA Library, Uros Markovic, 293492

CLINICAL OUTCOMES AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) AMONG RANDOMIZED CLINICAL TRIAL (RCT)-ELIGIBLE AND RCT-INELIGIBLE PATIENTS: RESULTS FROM THE CONNECT® MM REGISTRY

EHA Library, Lynne Wagner, 293496